Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Accounts Payables (2020 - 2026)

RxSight filings provide 6 years of Accounts Payables readings, the most recent being $5.3 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 16.55% to $5.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.3 million, a 16.55% increase, with the full-year FY2025 number at $5.3 million, up 16.55% from a year prior.
  • Accounts Payables hit $5.3 million in Q4 2025 for RxSight, up from $3.4 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $7.1 million in Q1 2025 to a low of $1.7 million in Q4 2021.
  • Median Accounts Payables over the past 5 years was $3.9 million (2023), compared with a mean of $3.8 million.
  • Biggest five-year swings in Accounts Payables: skyrocketed 146.72% in 2022 and later plummeted 34.29% in 2025.
  • RxSight's Accounts Payables stood at $1.7 million in 2021, then skyrocketed by 53.64% to $2.6 million in 2022, then surged by 48.86% to $3.9 million in 2023, then increased by 17.63% to $4.5 million in 2024, then increased by 16.55% to $5.3 million in 2025.
  • The last three reported values for Accounts Payables were $5.3 million (Q4 2025), $3.4 million (Q3 2025), and $3.3 million (Q2 2025) per Business Quant data.